The CHAnging Rare disorders of LysInE (CHARLIE) metabolism project is focused on develpoming new treatments for patients with pyridoxine-dependent epilepsy and glutaric aciduria type I. Novel therapies will be developed and validated using neuronal stem cells, zebrafish, and mouse models.